Questions to Ask Before Filling at a Compounding Pharmacy

Compounded GLP-1s have been a live subject for years, and the discussion around them tends to arrive in two flavors: a bargain or a scandal. Both flavors are wrong for the same reason, because compounded preparations are a regulated practice with a history and a rulebook, not a category of good or bad. Many people have used them under a prescriber's care. This page's job is narrower than the argument: the site already covers logging the doses at Tracking Compounded Semaglutide: Extra Care, Extra Notes, and this page covers the pharmacy.

The record matters because it is the part of the subject people half-remember. So the dates come first, plainly, and then the questions, which are the part that travels: the rules have moved repeatedly and may move again, but the questions to ask a pharmacy have barely changed at all.

503A and 503B, in plain language

The numbers refer to sections of federal law, and the difference between them is the first thing to know, because it determines which rules a given operation answers to. A 503A pharmacy is a state-licensed pharmacy that compounds for individual patients, against a prescription, the traditional model of a pharmacist making something specific for one person. It may not make essentially-copy drugs regularly or in inordinate amounts. FDA has said it does not intend to take action against a compounder regularly making essentially-copy products if that compounder fills four or fewer prescriptions of that product in a calendar month, and FDA framed that as applying at this time.

A 503B outsourcing facility is a different animal: it manufactures in larger volumes under different rules, and generally may not make a product identical or nearly identical to an FDA-approved drug unless that drug is on the FDA shortage list. The practical takeaway is not that one kind is safer than the other; it is that knowing which one is filling the prescription tells a person which rules and which questions apply.

The regulatory record, with dates

What follows is the dated record, stated as such. FDA first declared the tirzepatide shortage resolved on 2 October 2024. After litigation remanded that decision, FDA issued a new determination on 19 December 2024 finding the tirzepatide injection shortage resolved. On 21 February 2025, FDA announced that the shortage of semaglutide injection products was resolved. Once a shortage is resolved, FDA generally considers the drug to be commercially available, and that commercial availability is what governs whether copies are permitted.

The enforcement discretion periods that had allowed compounders to make these products then ended through 2025. For tirzepatide: after the 5 March 2025 court decision for 503A pharmacies, and on 19 March 2025 for 503B outsourcing facilities. For semaglutide: after the 24 April 2025 court decision for 503A, and on 22 May 2025 for 503B. As of 1 April 2026, tirzepatide and semaglutide appeared on neither the 503B bulks list nor the FDA drug shortage list.

And here is the part an honest page has to say plainly: this area has kept moving through 2026. Further proposals and litigation have continued since those dates, and the position stated above is the record as of the publication date of this article, not a prediction about tomorrow. Whether a specific preparation is permitted today is something a pharmacist and a prescriber can answer, and an article cannot. A reader who asks this question of a pharmacist will get a better answer than any web page can give, including this one.

GLP 1 Tracker AppWhen concentrations vary and doses are expressed differently, the log is the safety net: what was taken, when, and from which vial, recorded on your phone and nowhere else. Get the app

What is in it, and at what concentration

Two questions do most of the practical work. The first is what exactly is in the preparation. Compounded products are not always the same molecule in the same form as the approved product; salt forms and added ingredients are a real question, and the answer should come from the pharmacy, in writing. This is not an interrogation. Pharmacies answer composition questions routinely, and a written answer is the kind that can be shown to a prescriber or kept with the record.

The second question is the most practical safety question in the whole subject: what is the concentration, and how is the dose expressed? Compounded products are frequently dosed in units or millilitres rather than milligrams, and concentrations differ between pharmacies, which means a dose that means one thing at one concentration means something else at another. This is exactly why tracking a compounded preparation asks more of a log than tracking a branded pen does, and it is the subject of Tracking Compounded Semaglutide: Extra Care, Extra Notes, which covers units against milligrams, changing pharmacies mid-course, and what to write down each time.

Testing, labels and beyond-use dates

Then there are the questions that read as technical and are really about whether the operation is set up for its own work. Is the preparation tested, and by whom? Potency and sterility testing by an independent laboratory is a reasonable thing to ask about and a reasonable thing to be shown. What does the label on the vial say? A beyond-use date, storage instructions, a lot or batch identifier, and the name and strength of what is inside are the markings that let a person use the product correctly weeks later. A label that omits them is not a stylistic choice.

The last question is the quiet one: who do I call if something goes wrong? A pharmacy that fills a preparation is a pharmacy that answers for it, and having a name and a number before anything goes wrong is worth more than having them after. Alongside the clinical questions, it is worth asking which prescriber and pharmacy conversations belong together; if the prescription came through a telehealth service, the site's page of questions to ask before signing up covers the prescriber side of the same relationship.

What sits outside all of this

One boundary deserves its own paragraph. Everything above describes a regulated practice: a state-licensed pharmacy or a registered facility, a prescription, a labeled product, and someone accountable at the other end of a phone. Product sold without a prescription through a website or a social seller sits entirely outside all of the above, and no question on this page rehabilitates it. There is no version of that transaction where the questions apply, which is why this page states that boundary without hedging: it is not a third flavor of the same subject.

Inside the boundary, the honest summary is unglamorous. The regulatory record is dated, moving and answerable by professionals. The questions are stable, and a pharmacy that answers them plainly, in writing, without taking offense, is demonstrating the thing every question on this page is actually probing for: an operation that knows it is accountable for what it fills.